Gualtiero Palareti

TL;DR: Guyatt et al. as mentioned in this paper presented the pharmacokinetics and pharmacodynamics of vitamin K antagonists (VKAs) and provided specific management recommendations for the first 1 or 2 days for most individuals.

TL;DR: Caution is required in elderly patients and anticoagulation intensity should be closely monitored to reduce periods of overdosing and see fewer bleeding events than those recorded in other observational and experimental studies.

TL;DR: There is a large amount of evidence on laboratory and clinical characteristics of vitamin K antagonists and a growing body of evidence is becoming available on the first new oral anticoagulant drugs available for clinical use, dabigatran and rivaroxaban.

TL;DR: In this paper, the authors performed d-dimer testing 1 month after the discontinuation of anticoagulation in patients with a first unprovoked proximal deep-vein thrombosis or pulmonary embolism who had received a vitamin K antagonist for at least 3 months.

TL;DR: The present study shows that previous thrombosis and ACA titer > 40 U are independent predictors of thromBosis; history of miscarriage or vascular disease is significantly associated with adverse pregnancy outcome; and hematological malignancies can develop during follow-up in patients with antiphospholipid antibodies.